# Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

> **NCT05146284** · PHASE2 · WITHDRAWN · sponsor: **Poxel SA**

## Conditions studied

- Adrenomyeloneuropathy

## Interventions

- **DRUG:** PXL770

## Key facts

- **NCT ID:** NCT05146284
- **Lead sponsor:** Poxel SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding to initiate the study
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05146284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05146284, "Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05146284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*